ClinicalTrials.Veeva

Menu
E

Evolution Research Group | Clinical Pharmacology of Miami

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CTP-543
SSP-004184
Risankizumab
SPD602
Isavuconazole
SSP-004184SS
DA-1241
Navocaftor
Levoketoconazole
VI-0521

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 185 total trials

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

The purpose of this study is to evaluate the amount of mirikizumab (test) that gets into the blood stream and how long it takes the body to get rid o...

Active, not recruiting
Healthy
Drug: Citrate-Free Mirikizumab

Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics

Enrolling
Hepatic Insufficiency
Drug: Simufilam

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Si...

Invitation-only
Alzheimer Disease
Healthy
Drug: VG-3927
Drug: Placebo

This is a 3-part study that includes a Part A, Part B, and Part C. Part A will study the safety and tolerability of the study drug known as LY3537031...

Enrolling
Healthy
Obesity
Drug: LY3537031
Drug: Placebo

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens...

Active, not recruiting
Systemic Sclerosis
Other: Placebo
Drug: MK-2225

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in p...

Enrolling
Hepatic Impairment (HI)
Drug: Nemtabrutinib

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered t...

Not yet enrolling
Healthy
Hepatic Insufficiency
Drug: Olomorasib

The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.

Active, not recruiting
Healthy Volunteers
Drug: Risankizumab

The purpose of the study is to learn about:* how PF-07817883 is processed in the body of adult participants.* the safety of PF-07817883.These partici...

Enrolling
COVID-19
Drug: PF-07817883
New

This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.

Enrolling
Hepatic Impairment
Drug: Quizartinib

This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, b...

Enrolling
Obesity
Drug: Placebo to DA-1726
Drug: DA-1726

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

The primary objective of this study is to assess the safety and tolerability of AMG 513 after single and multiple doses.

Enrolling
Cardiometabolic Disease
Drug: Placebo
Drug: AMG 513

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measur...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide

Trial sponsors

Lilly logo
Shire logo
Bristol-Myers Squibb (BMS) logo
Merck Sharp & Dohme (MSD) logo
Gilead Sciences logo
AbbVie logo
Bayer logo
Amgen logo
Astellas logo
Concert Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems